The S&P BSE Sensex also ended lower, falling 0.83% to close at 82,500 points, and registered a weekly loss of over 1.06%.

Shares of Glenmark Pharmaceuticals Ltd on Friday jumped 10 per cent after the firm said it has signed a deal with AbbVie to commmercialise its underdevelopment drug aimed to treat cancer and ...

Glenmark Pharmaceuticals shares rallied 10% on Friday to reach a record high after its biotech subsidiary signed a ...

US biopharma company AbbVie has inked a $700 million deal with IGI Therapeutics to develop and sell ISB 2001, an experimental drug for blood cancer.

IGI has partnered with AbbVie to grant exclusive rights to globally develop, manufacture, and commercialise ISB 2001 across ...

TV18’s daily newsletter featuring the top 10 stories on markets, corporate updates, economic insights, and financial ...

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

US pharma major AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation today ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

AbbVie has struck an immuno-oncology licensing agreement with IGI Therapeutics that is potentially worth more than $1.9 billion to the clinical-stage biotechnology company.